323

Sorafenib

323 Publications Verification

Cat. No.: HY-10201

CAS No.: 284461-73-0

Purity: 99.92%

Synonyms: Bay 43-9006

Target:

Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family Ephrin Receptor PDGFR

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

323

Sorafenib tosylate

323 Publications Verification

Cat. No.: HY-10201A

CAS No.: 475207-59-1

Purity: 99.75%

Synonyms: Bay 43-9006 tosylate

Target:

Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

89

Ribociclib

89 Cited Publications

Cat. No.: HY-15777

CAS No.: 1211441-98-3

Purity: 99.94%

Synonyms: LEE011

Target:

CDK

Research Areas:

Neurological Disease Cancer

RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

89

Ribociclib hydrochloride

89 Cited Publications

Cat. No.: HY-15777A

CAS No.: 1211443-80-9

Purity: 99.93%

Synonyms: LEE011 hydrochloride

Target:

CDK

Research Areas:

Neurological Disease Cancer

RRibociclib (LEE011) hydrochloride is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

89

Ribociclib succinate

89 Cited Publications

Cat. No.: HY-15777B

CAS No.: 1374639-75-4

Purity: 99.93%

Synonyms: LEE011 succinate

Target:

CDK

Research Areas:

Neurological Disease Cancer

RRibociclib (LEE011) succinate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

89

Ribociclib succinate hydrate

89 Cited Publications

Cat. No.: HY-15777C

CAS No.: 1374639-79-8

Purity: 99.94%

Synonyms: LEE011 succinate hydrate

Target:

CDK

Research Areas:

Cancer

RRibociclib (LEE011) succinate hydrate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

79

Ro-3306

79 Cited Publications

Cat. No.: HY-12529

CAS No.: 872573-93-8

Purity: 98.68%

Target:

CDK Apoptosis

Research Areas:

Cancer

Ro-3306 is a potent and selective inhibitor of CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

41

NVP-2

41 Cited Publications

Cat. No.: HY-12214A

CAS No.: 1263373-43-8

Purity: 99.60%

Target:

CDK Apoptosis

Research Areas:

Cancer

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

25

ML364

25 Cited Publications

Cat. No.: HY-100900

CAS No.: 1991986-30-1

Purity: 99.96%

Target:

Deubiquitinase

Research Areas:

Cancer

ML364 is a selective ubiquitin specific peptidase 2 (USP2) inhibitor (IC₅₀=1.1 μM) with anti-proliferative activity, which direct binds to USP2 (K_d=5.2 μM), induces an increase in cellular cyclin D1 degradation and causes cell cycle arrest. ML364 increases the levels of mitochondrial ROS and decreases in the intracellular content of ATP .

Compare

loading...